Who to call at BioMarin Pharmaceutical, and when
Fundz watches for the moments BioMarin Pharmaceutical starts buying, and tells you who to reach.
- An alert the day BioMarin Pharmaceutical raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioMarin Pharmaceutical, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioMarin Pharmaceutical. With Fundz connected, it knows.
BioMarin Enters Exclusive License Agreement With GC Biopharma and Hanmi Pharm for HM15421/GC1134A to Treat Fabry Disease.
Contract Type
agreement
San RafaelBiotechnologyHealth CareMedicalGeneticsTherapeuticsDescription
BioMarin has signed an exclusive worldwide license agreement with GC Biopharma and Hanmi Pharm for the development and commercialization of HM15421/GC1134A, an enzyme replacement therapy for Fabry disease. The agreement includes an upfront payment of $70 million and further milestone payments and royalties.
Quick answer
BioMarin Enters Exclusive License Agreement With GC Biopharma and Hanmi Pharm for HM15421/GC1134A to Treat Fabry Disease. (October 29, 2026). BioMarin Pharmaceutical is based in San Rafael, California, United States.
- What agreement did BioMarin Pharmaceutical announce on October 29, 2026?
- BioMarin has signed an exclusive worldwide license agreement with GC Biopharma and Hanmi Pharm for the development and commercialization of HM15421/GC1134A, an enzyme replacement therapy for Fabry disease. The agreement includes an upfront payment of $70 million and further milestone payments and royalties.
- What does BioMarin Pharmaceutical do?
- BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery.
- Where is BioMarin Pharmaceutical based?
- BioMarin Pharmaceutical is based in San Rafael, California, United States.
- Which similar companies announced agreements around the same time?
- Alexion (October 29, 2026), Cognito Therapeutics (October 27, 2026), Georgiamune (October 25, 2026) and YD Bio Limited (October 20, 2026) also announced agreements within 45 days of BioMarin Pharmaceutical.
Source: Fundz verified event record.
Other recent agreements in Medical and Genetics
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Wolves Foundation and Alexion extend partnership to support Wolves Disability FC and Wolves Wishes for three more years. (October 29, 2026)
- Rhode Island Life Science Hub and Cognito Therapeutics launch partnership for Alzheimer's research. (October 27, 2026)
- Menarini and Georgiamune Enter $1.1 Billion License Agreement for Cancer Immunotherapy GIM-621. (October 25, 2026)
- YD Bio and EG BioMed Form Partnership with JoiiUp to Launch AI Cancer Risk Assessment for Corporate Wellness. (October 20, 2026)
- NVision Partners with HyperLight to Advance Photonic Quantum Chip Development. (October 28, 2026)
- Boston Scientific and Heartflow Form Strategic Partnership to Enhance PCI Planning. (October 28, 2026)
BioMarin Pharmaceutical signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.